Neuroone Medical Technologies (NMTC) Cash from Investing Activities (2017 - 2026)
Neuroone Medical Technologies (NMTC) posted Cash from Investing Activities of -$38516.0 for Q1 2026, up 5.49% on a QoQ basis from -$40754.0 in Q4 2025, and down 1114.63% year-over-year from $3796.1 in Q1 2025.
Neuroone Medical Technologies (NMTC) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Neuroone Medical Technologies' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$38516.0 for Q1 2026.
- Quarterly Cash from Investing Activities fell 1114.63% year-over-year to -$38516.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$133425.0 (down 68.27% YoY) and the FY2025 annual result came in at -$81742.0, up 31.99% from the prior year.
- Cash from Investing Activities was -$38516.0 for Q1 2026 at Neuroone Medical Technologies, up from -$40754.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $1.8 million in Q1 2023 and bottomed at -$3.0 million in Q3 2022.
- A 5-year average of -$47912.9 and a median of -$36905.0 in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 8546.56% — and 2023, when it surged 2054.91%.
- Neuroone Medical Technologies' Cash from Investing Activities stood at $15069.0 in 2022, then slumped by 346.41% to -$37131.0 in 2023, then jumped by 34.24% to -$24416.0 in 2024, then sank by 66.92% to -$40754.0 in 2025, then grew by 5.49% to -$38516.0 in 2026.
- Business Quant data shows NMTC's Cash from Investing Activities at -$38516.0 in Q1 2026, -$40754.0 in Q4 2025, and -$10607.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -298.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -475.32 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -2.50 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Neuroone Medical Technologies | 7.99 Mn | 5.19 Mn | 990,264.00 | -38,516.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38,516.00 |
| Mar 31, 2026 | -38,516.00 |
| Dec 31, 2025 | -40,754.00 |
| Dec 31, 2025 | -40,754.00 |
| Sep 30, 2025 | -10,607.00 |
| Sep 30, 2025 | -10,607.00 |
| Jun 30, 2025 | -43,548.00 |
| Jun 30, 2025 | -43,548.00 |
| Mar 31, 2025 | -3,171.00 |
| Mar 31, 2025 | -3,171.00 |
| Dec 31, 2024 | -24,416.00 |
| Dec 31, 2024 | -24,416.00 |
| Sep 30, 2024 | -36,905.00 |
| Sep 30, 2024 | -36,905.00 |
| Jun 30, 2024 | -14,801.00 |
| Jun 30, 2024 | -14,801.00 |
| Mar 31, 2024 | -31,360.00 |
| Mar 31, 2024 | -31,360.00 |
| Dec 31, 2023 | -37,131.00 |
| Dec 31, 2023 | -37,131.00 |